Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.

Hye Won LeeYoung Youn ChoHyein LeeJae Seung LeeSeung Up KimJun Yong ParkDo Young KimSang Hoon AhnBeom Kyung KimSoo Young Park

Published in: Hepatology international (2021)

These findings suggest that ETV- and TAF-treated CHB patients have similar risk of developing HCC. Further studies with the larger sample size and longer follow-up are needed to validate these results.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
hepatitis b virus
prognostic factors
patient reported outcomes
case control